We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ipso Ventures | IPS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.425 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.425 | 1.425 |
| Top Posts |
|---|
Posted at 31/1/2013 20:40 by double6 CGG - similar to IPS, raising funds for investments...capped at £200k......Todays RNS seems to have gone unnoticed... They have another £100k being raised (at 60p), with investors including the renowned Bruce Rowan. They already have Investments at £100k. They have Mark Parker on board (ex-African Eagle, capped at £20mln), who is the main shareholder and Managing Director of Equator Gold, an unlisted exploration company focused on exploring for gold in the new state of Southern Sudan. So for a company that will be capped at less than £300k once the funds are raised, we will have around £250k of Assets, as well as Mark Parker on board who could well be lining up CGG for a RTO of Equator Gold (?). Whatever the score, this looks like a no-brainer when we've seen other Cash Shells raise funds and subsequently see their share price sore on speculation of investments / RTO's. Interesting...... |
Posted at 16/12/2012 13:44 by theshareguru results very soon and update, this could turn out to be very interestingif deal goes through with new investor on board and old investments put into newco where we will get benefit when they are sold instead of having to file sale. It seems that there was more than one interested party , to invest in ipso, which almost will change it's name in line with area of investment hope it's oil and gas, 2013 hopefully will give us a new company and better chances. one thing to remember is that ipso's original investments where worth alot more than suspended value. therakind could be sold on in time for at least 70% of suspended market cap alone, as they have 36%. |
Posted at 15/6/2012 07:55 by howdlep That makes Andrew Hobbs the largest shareholder now. Previously..... |
Posted at 28/3/2012 13:33 by howdlep Yes I am expecting news re Therekind product pipeline. This from the Interim statement:-Therakind Therakind is a paediatric healthcare company. It takes known adult drugs and creates a version for children which can be protected by EU legislation. The revenue model is to generate royalties on product sales. Therakind's major success in 2011 was the securing of the first PUMA (Paediatric Use Marketing Authorisation) for its first product, Buccolam. This product has been licenced to Viropharma Inc who have launched the product in the UK to be followed by launches in other European countries. Therakind has received certain upfront payments and will receive royalties on sales of Buccolam. Therakind is co-developing a pipeline of products with a number of partners. These products are at various stages of development and include one which is in late stage development. Therakind is based in London and other investors include University College London, private investors, management and the academic founder. IPSO's shareholding is 36%. |
Posted at 10/2/2012 08:48 by howdlep pezza4,Excellent purchase imo. I am expecting value enhancing news from three of IPS' investments in due course, namely Biocroi, IPSol Energy and in particular Therakind. For those new to this bb, here is a little about Therakind, taken from the Half Year report:- (note, that one product is at a late stage of development) "Therakind is a paediatric healthcare company. It takes known adult drugs and creates a version for children which can be protected by EU legislation. The revenue model is to generate royalties on product sales. Therakind's major success in 2011 was the securing of the first PUMA (Paediatric Use Marketing Authorisation) for its first product, Buccolam. This product has been licenced to Viropharma Inc who have launched the product in the UK to be followed by launches in other European countries. Therakind has received certain upfront payments and will receive royalties on sales of Buccolam. Therakind is co-developing a pipeline of products with a number of partners. These products are at various stages of development and include one which is in late stage development. Therakind is based in London and other investors include University College London, private investors, management and the academic founder. IPSO's shareholding is 36%" |
Posted at 09/2/2012 10:39 by howdlep I am looking for management to engineer an exit strategy for two of their leading investments. This from the interims:-Biocroi and IPSol Energy, both raised new funds from third party investors at improved valuations. Here are the Company's current investments:- Portfolio companies Axilica Axilica provides a unique behavioural synthesis tool in the ESL (electronic system level) design automation market. The advanced section of the ESL market has been dominated by small technology vendors and start-ups offering synthesis tools focused on translating programming languages (C, C++) into hardware (FPGA, ASIC). Axilica has continued to work closely, either directly or through funded European research projects, with leading embedded systems companies including Selex Galileo Ltd, Thales Communications & Security SA and Intracom SA. Axilica has actively enhanced its product, FalconML, to meet the needs of customers in its selected markets which include military/aerospace and telecoms. These enhancements have been specified by Axilica's customers and represent unique capabilities for the design of complex electronic embedded systems. In response to customer needs, Axilica is now providing expert services to guide designers in the use of its technology on new embedded platforms. These services include proof of concept designs and customised support for specific embedded platforms. Axilica is based in Loughborough and other investors include Loughborough University, the Lachesis Fund and the founding academics. IPSO's shareholding is 45%. Biocroi Biocroi has designed and developed a range of unique advanced microplates using gel-based buffering systems surrounding the wells which leads to better control of the microplate environment, which in turn improves quality, accuracy and uniformity of results. Biocroi's advanced microplate designs enable users to reduce costs, shorten development times and increase data quality. Biocroi is working with a variety of partners to develop its products. These include a major pharmaceutical company and a leading supplier of genomics products to the drug discovery and development industry. Prototype products have been developed and volume production is expected to start in 2012. Biocroi secured significant funding from Kernel Capital and Enterprise Ireland in 2011 and has been able to significantly increase its operations since securing additional funding. Biocroi is based in Dublin and other investors include Kernel Capital, Enterprise Ireland, certain private investors and the academic founder. IPSO's shareholding is 6%. Cambridge Meditech Cambridge Meditech's novel patented wound infection technology gives a visual indication of infection. Wound infection can be detected without unnecessary disruption to a dressing and appropriate intervention can be made immediately. It is anticipated that the products will have multiple applications in various settings. Our partner, Lantor, is continuing to work on products which incorporate Cambridge Meditech's technology and has had discussions with a number of potential customers. Cambridge Meditech is based at IPSO's offices and is 100% owned by IPSO. IPSol Energy IPSol Energy is a service business providing testing, certification and other services to the solar photovoltaic ("PV") industry. In 2011 IPSol Energy achieved UKAS accreditation for its solar PV laboratory, making it the first of its kind in the UK. IPSol Energy has carried out work for a range of customers across the UK solar PV industry generating good revenues in its first year of operation. In October 2011 IPSol Energy secured additional funding from investors which has allowed it to expand its testing capability. 2011 saw a huge increase in the UK PV market with the introduction of feed in tariffs for generating solar electricity but the recent changes to these tariffs by the UK Government will change things in the coming year. IPSol Energy has secured strategic partnerships with a major international testing business and the BSI Group (British Standards Institution) which is anticipated will lead to additional business from outside the UK. IPSol Energy is based in Nottingham and other shareholders include Loughborough University, certain private investors, management and the academic founder. IPSO's shareholding is 27%. Medermica Medermica has so far been unsuccessful in licencing its ph measurement technology to third parties. It has recently taken its patents into the PCT national/regional phase in Europe and US. Further significant business development is prevented through a lack of funding but the company is endeavouring to identify ways which the business can progress. Medermica is based at IPSO's offices and is 75% owned by IPSO and 25% by Imperial Innovations plc. Polyfect Solutions Polyfect's novel process enables cost savings and quality improvements to a range of plastics through the highly efficient incorporation of functional fillers (which give polymers certain characteristics and properties). Polyfect is continuing its development work with a major international brewer and has recently commenced a feasibility study with a consumer products multinational. Discussions with other interested parties are also taking place with a view to exploiting Polyfect's technology particularly in the nanotechnology area. Additionally Polyfect has secured Technology Strategy Board funding for a project on improved food packaging. Additional patent filings are planned in the coming year. Polyfect is based in Loughborough and other shareholders include Loughborough University, the Lachesis Fund and the academic founders. IPSO's shareholding is 33%. Therakind Therakind is a paediatric healthcare company. It takes known adult drugs and creates a version for children which can be protected by EU legislation. The revenue model is to generate royalties on product sales. Therakind's major success in 2011 was the securing of the first PUMA (Paediatric Use Marketing Authorisation) for its first product, Buccolam. This product has been licenced to Viropharma Inc who have launched the product in the UK to be followed by launches in other European countries. Therakind has received certain upfront payments and will receive royalties on sales of Buccolam. Therakind is co-developing a pipeline of products with a number of partners. These products are at various stages of development and include one which is in late stage development. Therakind is based in London and other investors include University College London, private investors, management and the academic founder. IPSO's shareholding is 36%. Wildknowledge Wildknowledge creates mobile applications that engage audiences with their heritage (i.e. the environment, wildlife, archaeology and history). Its offering includes data gathering applications; location based content and engaging games. Wildknowledge has a range of customers including: National Geographic; The British Museum, RSPB, Wildlife Trust and the Heritage Lottery Fund and is in discussions regarding a number of other contracts in this field for 2012. In addition, Wildknowledge has enjoyed success in the e-health market with a range of rapid assessment tools and has also received TSB funding to examine the feasibility of using smartphones to monitor and motivate movement in the elderly at home. 2011 has seen Wildknowledge reduce its reliance on the education market and build revenues through three streams (white labelling existing technology, delivery of native applications/subscri Wildknowledge is based in Oxford and other investors include Oxford Brookes University, certain private investors and the academic founders. IPSO's shareholding is 9%. Craig Rochford Executive Chairman 23 January 2012 |
Posted at 09/2/2012 10:07 by howdlep Has this one been missed by the market?Market cap is @ £1.2m @ 3p Illiquid and will move with nearly every trade. No debt. 8 February 2012 Directors and a consultant take shares in lieu of fees. Always a good sign of where the share price is going. Interims 23 January 2012 Cash and short term investments at 31 October 2011 totalled GBP40,670. This is sufficient until Q3 2012 even if management do not realise profits from any of their 8 investments, five of which are already revenue generating. The other 3 are I.P based. Executive Chairman statement:- "We are delighted to record our first modest net profit in this period. This was principally as a result of increases in the valuation of two portfolio companies, Biocroi and IPSol Energy, during the period. Both companies raised new funds from third party investors at improved valuations. The Company's net profit for the period under review was GBP27,666 (six months to 31 October 2010: loss after tax of GBP230,128). Investment activities Financial constraints prevented us from making any new investments during the period. We recorded an increase of GBP88,338 and GBP110,625 in the fair value of our investments in Biocroi and IPSol Energy respectively. This has increased the fair value of our investment portfolio by GBP198,963 to GBP1.896 million (30 April 2011: GBP1.697 million). We have also been working with our portfolio companies to add value and, where appropriate, position them for exit. Financing Following the fundraising in July 2011 and the reductions in costs the Board believe that the Company has sufficient funding to take it into the third quarter of 2012 without assuming any revenues from the sales of any investments. Operating costs Corporate operating costs were reduced further during the period compared to the same period last year. In addition all directors' fees are being paid in new ordinary shares in IPSO thereby reducing the cash operating costs of the Company. Cash Cash and short term investments at 31 October 2011 totalled GBP40,670." |
Posted at 25/1/2012 11:22 by howdlep I have taken a small position following the recent Interims. NAV 1.896m v market cap of £1.1m at 2.875p. That is obviously common place for this type of stock, but with working capital until Q3, without realising any profits from current investments, as well as having access to new money, IPS are well positioned to realise value for its shareholders.This will move quickly with one or two buys. IPSO Ventures 23 January 2012 | 09:05am StockMarketWire.com - IPSO Ventures posts its first net profit for the six months to the end of October. This was principally a result of increases in the valuation of two portfolio companies, Biocroi and IPSol Energy, during the period. Both companies raised new funds from third party investors at improved valuations. The company's net profit for the period was £27,666 compared with an after-tax loss of £230,128 last time. Executive chairman Craig Rochford said: "Financial constraints prevented us from making any new investments during the period. "We recorded an increase of £88,338 and £110,625 in the fair value of our investments in Biocroi and IPSol Energy respectively. "This has increased the fair value of our investment portfolio by £198,963 to £1.896m (30 April 2011: £1.697m). "We have also been working with our portfolio companies to add value and, where appropriate, position them for exit. "Following the fundraising in July 2011 and the reductions in costs the board believe that the company has sufficient funding to take it into the third quarter of 2012 without assuming any revenues from the sales of any investments. "Corporate operating costs were reduced further during the period compared to the same period last year. "In addition all directors' fees are being paid in new ordinary shares in IPSO thereby reducing the cash operating costs of the company." --- Nice 61.8% retracement. Time to buy for the next leg up? |
Posted at 23/1/2012 09:43 by jormes Sorry Pugugly but I don't agree with you on the future. While the previous management may have been over optimistic, the chairman states that "Access to additional capital from investors if good investment opportunities present themselves". So clearly they have access to funding if necessary and he goes on to state "The Board is also looking at a number of opportunities which the Board believe have potential to significantly enhance shareholder value". So not withstanding the 8 companies they currently own stakes in, no debt, cash for day to day operations until Q3 and the potential acquisitions IMHO definitely undervalued at 1.35m (3.5p). |
Posted at 15/9/2011 15:48 by troutisout Well for any long term investors the question has got to be why they waited until now to release the RNS? It was approved over a week ago. Why wait until investors are telling them to issue the News? |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
